Skip to main content

Table 3 Association of thyroid hormones with rapid eGFR decline during follow-up

From: Thyroid hormones associate with risk of incident chronic kidney disease and rapid decline in renal function: a prospective investigation

  Case/number (%) Model 1 Model 2 Model 3
Serum FT4
 Tertile 1 40/699 (5.7) 1.00 1.00 1.00
 Tertile 2 56/701 (8.0) 1.40 (0.92–2.14) 1.38 (0.89–2.12) 1.40 (0.91–2.16)
 Tertile 3 69/703 (9.8) 1.72 (1.15–2.59) 1.61 (1.06–2.45) 1.64 (1.07–2.50)
 P for trend 0.0004 0.009 0.03 0.02
 Each 1-pmol/l increase in FT4 165/2103 (7.9) 1.12 (1.05–1.21) 1.10 (1.02–1.18) 1.10 (1.03–1.18)
Serum FT3
 Tertile 1 55/687 (8.0) 1.00 1.00 1.00
 Tertile 2 69/712 (9.7) 1.29 (0.89–1.87) 1.35 (0.91–1.99) 1.36 (0.92–2.00)
 Tertile 3 41/704 (5.8) 0.79 (0.51–1.21) 0.84 (0.54–1.30) 0.83 (0.53–1.30)
 P for trend 0.025 0.33 0.50 0.49
 Each 1-pmol/l increase in FT3 165/2103 (7.9) 1.17 (0.95–1.44) 1.14 (0.93–1.40) 1.13 (0.92–1.39)
Serum TSH
 Tertile 1 63/700 (9.0) 1.00 1.00 1.00
 Tertile 2 53/700 (7.6) 0.77 (0.53–1.14) 0.85 (0.57–1.26) 0.85 (0.57–1.26)
 Tertile 3 49/703 (7.0) 0.67 (0.44–0.99) 0.75 (0.50–1.15) 0.74 (0.49–1.14)
 P for trend 0.35 0.046 0.18 0.17
 Each 1-μIU/ml increase in TSH 165/2103 (7.9) 0.97 (0.88–1.08) 1.00 (0.92–1.08) 1.00 (0.92–1.08)
  1. Model 1: adjusted for age, sex, BMI at baseline
  2. Model 2: further adjusted for triglyceride, HDL-c, diabetes and hypertension status, current smoking and drinking status, use of antihypertensive drugs, use of antidiabetic drugs, eGFR at baseline
  3. Model 3: Further adjusted for TPOAb, TGAb at baseline
  4. P for trend values for percentages of rapid eGFR decline are calculated by using Cochran–Mantel–Haenszel (CMH) method
  5. Data are odds ratios (95% confidence intervals)
  6. BMI body mass index, eGFR estimated glomerular filtration rate, FT3 free triiodothyronine, FT4 free thyroxine, HDL-c high-density lipoprotein cholesterol, TSH thyroid-stimulating hormone, TPOAb thyroid peroxidase antibody, TGAb thyroglobulin antibody